Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination topical analgesic product containing **ibuprofen**, **methyl salicylate**, ****menthol**, **camphor**, and **eucalyptus oil**. The combination is primarily intended for the symptomatic relief of **acute musculoskeletal pain**, including minor aches and pains of muscles and joints associated with backache, arthritis, strains, bruises, and sprains. Each component contributes either anti-inflammatory (ibuprofen), counterirritant, or analgesic properties. **Ibuprofen** is a nonsteroidal anti-inflammatory drug (NSAID) acting mainly via inhibition of cyclooxygenase enzymes, reducing the synthesis of prostaglandins responsible for pain and inflammation[4]. **Methyl salicylate**, **menthol**, and **camphor** are counterirritants that create sensations of coolness or warmth to temporarily mask underlying pain and discomfort[1][3]. **Eucalyptus oil** may provide additional analgesic, anti-inflammatory, or aromatic effects though evidence is largely traditional. The combination does not cure underlying disease but alleviates pain where applied topically[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + methyl salicylate + menthol + camphor + eucalyptus oil.